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PCoronary Artery Disease Risk
Serum Myeloperoxidase Levels Are
Associated With the Future Risk of Coronary
Artery Disease in Apparently Healthy Individuals
The EPIC-Norfolk Prospective Population Study
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Joram N. van Miert, BSC,* Jan Albert Kuivenhoven, PHD,* Robert G. Schaub, PHD,§
Nicholas J. Wareham, MB, PHD, Robert Luben, BSC,# John J. P. Kastelein, MD, PHD,*
Kay-Tee Khaw, MBBCHIR,# S. Matthijs Boekholdt, MD, PHD*†
Amsterdam, the Netherlands; Cleveland, Ohio; Cambridge, Massachusetts; and Cambridge, United Kingdom
Objectives We evaluated whether serum myeloperoxidase (MPO) levels are associated with the risk of future development
of coronary artery disease (CAD) in apparently healthy individuals.
Background An enzyme of the innate immune system, MPO exhibits a wide array of proatherogenic effects. These include
induction of oxidative damage to low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol and
promotion of plaque vulnerability. Recent studies revealed that MPO independently predicts adverse outcomes
in patients with chest pain or suspected acute coronary syndrome.
Methods Myeloperoxidase was measured in baseline samples of a case-control study nested in the prospective EPIC
(European Prospective Investigation into Cancer and Nutrition)-Norfolk population study. Case subjects
(n  1,138) were apparently healthy men and women who developed CAD during 8-year follow-up. Control sub-
jects (n  2,237), matched for age, gender, and enrollment time, remained free of CAD.
Results The MPO levels were significantly higher in case subjects than in control subjects and correlated with C-reactive
protein (CRP) (  0.25; p  0.001) and white blood cell count (  0.33; p  0.001). Risk of future CAD in-
creased in consecutive quartiles of MPO concentration, with an odds ratio (OR) of 1.49 in the top versus bottom
quartile (95% confidence interval [CI] 1.20 to 1.84; p  0.001). After adjustment for traditional risk factors, the
OR in the top quartile remained significant at 1.36 (95% CI 1.07 to 1.73). Elevated MPO levels (728 pmol/l)
similarly predicted increased risk of future CAD among participants with either LDL-cholesterol 130 mg/dl,
HDL-cholesterol 50 mg/dl, or CRP 2.0 mg/l (OR 1.52 [95% CI 1.21 to 1.91], 1.59 [95% CI 1.24 to 2.05], and
1.42 [95% CI 1.14 to 1.77)], respectively).
Conclusion Elevated MPO levels predict future risk of CAD in apparently healthy individuals. This study suggests that inflam-
matory activation precedes the onset of overt CAD by many years. (J Am Coll Cardiol 2007;50:159–65)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.03.033e
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Wnflammation plays a key role in the initiation and progres-
ion of atherosclerosis (1). For clinical evaluation,
-reactive protein (CRP) is gradually gaining acceptance as
marker of inflammation (2). Recent studies have also
rawn attention to myeloperoxidase (MPO), one of the
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f cardiovascular disease (CVD) and a potential target for
reatment (3).
Traditionally, MPO was considered to be a bactericidal
gent (4), but recent studies have emphasized the impor-
led by the Cleveland Clinic Foundation that relate to the use of myeloperoxidase as a
iomarker for cardiovascular disease. The EPIC-Norfolk study is supported by program
rants from the Medical Research Council UK and Cancer Research UK, with additional
upport from the European Union, Stroke Association, British Heart Foundation, and the
ellcome Trust. Chris Cannon, MD, acted as the Guest Editor for this article.
Manuscript received November 27, 2006; revised manuscript received February 27,
007, accepted March 2, 2007.
e
a
u
a
c
h
c
p
r
w
p
T
a
w
h
f
f
(
m
c
M
S
a
I
c
s
d
d
E
b
t
K
s
w
B
o
s
c
v
p
u
w
i
W
h
a
C
a
r
2
N
a
P
i
s
i
d
f
m
g
B
H
s
U
l
c
u
o
e
p
i
a
N
r
C
t
f
s
m
(
i
l
l
o
S
l
t
s
i
160 Meuwese et al. JACC Vol. 50, No. 2, 2007
MPO and Future Risk of CAD July 10, 2007:159–65tance of MPO in CVD progres-
sion. The principal sources of
MPO are activated neutrophils
and monocytes. Myeloperoxidase
has been identified in human
plaques (5) and exerts potent
proatherogenic effects. These in-
clude oxidation of low-density
lipoprotein (LDL), rendering it
atherogenic (6), as well as oxida-
tive modification of apolipopro-
tein (apo) AI, attenuating its ca-
pacity to promote cholesterol
efflux (7,8). Myeloperoxidase ac-
tivity also diminishes nitric oxide
bioavailability, which leads to en-
dothelial dysfunction (9 –11).
This combination of detrimental
ffects has culminated in the concept that MPO may be an
ctive mediator of atherogenesis (3).
Moreover, MPO may play a role in the transition to
nstable plaque. Myeloperoxidase-induced hypochlorous
cid promotes endothelial cell apoptosis and detachment,
ausing superficial erosions (12). Indeed, MPO levels are
igher in patients with coronary artery disease (CAD) and
an predict future cardiovascular events in these patients and
atients with chest pain even after correction for traditional
isk factors and CRP (13–15).
However, in most of these clinical studies blood samples
ere obtained in an acute setting or when overt CAD was
resent. This may have affected MPO levels substantially.
hus far, data among individuals free of heart disease are
bsent. The purpose of the present study was to determine
hether elevated concentrations of MPO in apparently
ealthy individuals are associated with an increased risk of
uture CAD and how this relates to other cardiovascular risk
actors (e.g., LDL-cholesterol, high-density lipoprotein
HDL) cholesterol, and CRP). For this purpose, we deter-
ined serum MPO levels in a large prospective nested
ase-control study.
ethods
tudy design. We performed a nested case-control study
mong participants of the EPIC (European Prospective
nvestigation Into Cancer and Nutrition)-Norfolk study, a
ommunity-based prospective population study. The EPIC
tudy, a collaborative study of 9 countries in Europe, was
esigned to assess the determinants of cancer and other
iseases. The EPIC-Norfolk cohort, which is part of the
PIC study, has been described in detail previously (16). In
rief, investigators recruited 25,663 men and women be-
ween 40 and 79 years old, all residents of Norfolk, United
ingdom, from general practices and performed a baseline
urvey between 1993 and 1997. Nonfasting blood samples
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
BMI  body mass index
CAD  coronary artery
disease
CRP  C-reactive protein
CVD  cardiovascular
disease
HDL  high-density
lipoprotein
LDL  low-density
lipoprotein
MPO  myeloperoxidase
OR  odds ratioere obtained by venipuncture into plain and citrate bottles. mlood samples for assay were processed at the Department
f Clinical Biochemistry, University of Cambridge, or
tored at80°C. All individuals have been flagged for death
ertification at the U.K. Office of National Statistics, with
ital status ascertained for the entire cohort. In addition,
articipants admitted to hospital were identified using their
nique National Health Service number by data linkage
ith the East Norfolk Health Authority database, which
dentifies all hospital contacts throughout England and
ales for Norfolk residents. Participants were identified as
aving CAD during follow-up if they had a hospital
dmission and/or died with CAD as underlying cause.
oronary artery disease was defined as code 410 to 414
ccording to the International Classification of Diseases-9th
evision. We report results with follow-up to November
003, an average of 8 years. The study was approved by the
orwich District Health Authority Ethics Committee, and
ll participants gave informed consent.
articipants. For the present analysis, we only considered
ndividuals who did not report a history of heart attack or
troke at the baseline clinic visit. Case subjects were 1,138
ndividuals in whom fatal or nonfatal CAD developed
uring follow-up. Control subjects (n  2,237) remained
ree of CAD during follow-up. Two control subjects were
atched to each case subject by gender, age (within 5 years),
eneral practice, and date of visit (within 3 months).
iochemical analyses. Serum levels of total cholesterol,
DL-cholesterol, and triglycerides were measured on fresh
amples with the RA 1000 (Bayer Diagnostics, Basingstoke,
nited Kingdom). The LDL-cholesterol levels were calcu-
ated using the Friedewald formula. From 1994, full blood
ount was additionally measured on fresh EDTA samples
sing a Coulter counter. This measure is available for 60%
f the cohort. The CRP levels were measured with an
nzyme-linked immunosorbent assay (ELISA) in which
olyclonal rabbit anti-CRP antibodies were used as captur-
ng antibodies and biotinylated monoclonal antibodies
gainst CRP (CLB anti–CRP-2, Sanquin, Amsterdam, the
etherlands) as the detecting antibodies. Results were
elated to a standard consisting of commercially available
RP (Behringwerke, Marburg, Germany). The lower de-
ection limit of CRP was 0.1 mg/l. In 2005, serum samples
or case and control subjects were retrieved from frozen
torage and thawed, and serum concentration of MPO was
easured by use of a commercially available ELISA
CardioMPO Test, Prognostix, Cleveland, Ohio). The
nterassay and intra-assay variabilities were 2% and 6%. The
ower detection limit was 13 pmol/l, and the upper detection
imit was 5,223 pmol/l. Samples were analyzed in random
rder to avoid systemic bias and in a blinded fashion.
tatistical analysis. The MPO, CRP, and triglyceride
evels had a skewed distribution and were therefore log-
ransformed before being used as continuous variables in
tatistical analyses. Log transformation successfully normal-
zed the distribution. In tables we show untransformededians and corresponding interquartile range (IQR).
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July 10, 2007:159–65 MPO and Future Risk of CADaseline characteristics were compared between case and
ontrol subjects using a mixed effect model for continuous
ariables or conditional logistic regression for categoric
ariables, which takes into account the matching for gender,
ge, and enrollment time. Mean risk factor levels per MPO
uartile were calculated. Associations between MPO quar-
iles and traditional risk factors were calculated using linear
egression for continuous variables and the chi-square test
or trend for categoric variables. In addition, Pearson
orrelation coefficients were calculated to assess the relation-
hip between log-transformed MPO levels and other con-
inuous risk factors. Conditional logistic regression analysis
as used to calculate odds ratios (OR) and corresponding
5% confidence intervals (CI) as an estimate of the relative
isk of incident CAD, taking into account the matching for
ender, age, and enrollment time. The MPO concentrations
ere analyzed as categoric variables after division into
uartiles based on the distribution in control subjects as well
s a continuous variable. The lowest quartile was used as
eference category. The ORs were adjusted for the following
ardiovascular risk factors: systolic blood pressure, LDL-
holesterol, HDL-cholesterol, body mass index (BMI) (all
s continuous variables), smoking, and diabetes mellitus.
he ORs were also estimated after additional adjustment
or CRP (as continuous variable). In addition, the area
nder the receiver-operating characteristic curve (AUC) was
alculated for each risk factor to determine its discriminative
apacity. To assess whether MPO levels had predictive value
n top of the Framingham risk score, both variables were
ntered into a conditional logistic regression model (taking
nto account the matching for gender, age, and time of
nrollment), and the cumulative AUC was calculated. The
ramingham risk score was calculated using a previously
Characteristics of Study Participants
Table 1 Characteristics of Study Participant
Con
(n  2
Male, % (n) 63.1 (1
Age, yrs 65.3
Diabetes, % (n) 1.8 (4
Smoking, % (n)
Current 8.2 (1
Former 51.2 (1
Never 40.4 (8
Body mass index, kg/m2 26.3
Systolic blood pressure, mm Hg 139.1
Diastolic blood pressure, mm Hg 83.6
Total cholesterol, mg/dl 242
LDL-cholesterol, mg/dl 157
HDL-cholesterol, mg/dl 53
Triglycerides, mg/dl 142 (1
CRP, mg/l 1.5 (0
White cell count, 103 cells/mm2 6.5
Serum MPO concentration, pmol/l 638 (4
Data are presented as mean  SD, median (interquartile range), or %
analysis, but untransformed medians are presented.
CRP  C-reactive protein; HDL  high-density lipoprotein; LDL  low-densieported algorithm, which takes into account age, gender,
otal cholesterol, HDL-cholesterol, systolic and diastolic
lood pressure, smoking, and the presence of diabetes (17).
ugmentation of the AUC has been put forward as the best
ay to evaluate the incremental value of a parameter (18).
e used bootstrapping of receiver operating characteristic
urves to calculate statistical significance of the differences
etween both AUCs (19,20). Statistical analyses were per-
ormed using SPSS software (version 12.0.2, SPSS Inc.,
hicago, Illinois). A p value of 0.05 was considered to be
tatistically significant.
esults
haracteristics of participants. A total of 342 (30%) of
,138 cases died of coronary heart disease. The remaining
ases suffered nonfatal CAD events. Owing to matching,
ge was comparable between case and control subjects. As
xpected, individuals in whom CAD developed during
ollow-up were more likely than control subjects to smoke
nd have diabetes (Table 1). In line, cholesterol levels,
ystolic and diastolic blood pressure, BMI, leukocyte count,
nd CRP were significantly higher in case subjects than in
ontrol subjects, whereas HDL-cholesterol levels were sig-
ificantly lower in case subjects than in control subjects.
aseline serum MPO levels in case and control sub-
ects. Median serum MPO levels were higher in case
ubjects (median 704 [IQR 492 to 1,021] pmol/l) than in
ontrol subjects (638 [IQR 454 to 951] pmol/l; p  0.001)
Table 1). Furthermore, median serum MPO levels were
ignificantly higher in men than in women (680 [IQR 481
o 1,013] pmol/l vs. 619 [IQR 448 to 904] pmol/l; p 
.001). Among men, MPO levels in case subjects (734
Case
(n  1,138) p Value
63.7 (725) matched
65.5 7.8 matched
6.6 (75) 0.001
0.001
15.3 (172)
52.6 (592)
32.1 (361)
27.3 3.9 0.001
143.9 18.9 0.001
85.8 12.0 0.001
251 48 0.001
165 40 0.001
49 14 0.001
4) 168 (124–248) 0.001
) 2.4 (1.1–5.0) 0.001
6.9 2.1 0.001
1) 704 (492–1,021) 0.001
lyceride, CRP, and MPO concentrations were log-transformed befores
trol
,237)
,411)
7.7
1)
81)
,138)
94)
3.5
17.8
11.1
45
39
16
06–20
.7–3.1
1.7
54–95
(n). Trigty lipoprotein; MPO  myeloperoxidase.
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MPO and Future Risk of CAD July 10, 2007:159–65IQR 516 to 1,061] pmol/l) were significantly higher than
n control subjects (657 [IQR 464 to 985] pmol/l; p 
.001). Among women, there was a trend toward higher
PO levels in case subjects (660 [IQR 456 to 952] pmol/l)
s. 607 [IQR 446 to 894] pmol/l; p  0.098). In addition,
aseline MPO levels were significantly higher in subjects
ith fatal compared with nonfatal CAD (789 [IQR 529 to
,133] pmol/l vs. 681 [IQR 480 to 961] pmol/l; p 0.001).
thnic differences could not be addressed in this study.
erum MPO levels and other CAD risk factors. Table 2
ummarizes the distribution of CAD risk factors by MPO
uartiles. The strongest linear positive associations with
erum MPO were observed for CRP and white blood cell
ount (Table 2). For HDL-cholesterol, we identified a
inear negative association with serum MPO. The MPO
evels were also related to smoking habit. There was no
ssociation with other traditional risk factors.
erum MPO levels and risk of future CAD. The risk of
uture CAD increased in consecutive MPO quartiles so that
istribution of CAD Risk Factors by MPO Quartile
Table 2 Distribution of CAD Risk Factors by MPO Quartile
MPO Qu
1 2
MPO range, pmol/l 454 454–638
Case/control 219/559 276/560
Male/female, % 58/42 63/37
Age, yrs 64.7 8.0 65.3 7.5
Diabetes, % (n) 3.1 (24) 3.7 (31)
Smoking, % (n)
Current 6.6 (51) 9.5 (79)
Former 50.5 (389) 51.9 (430)
BMI, kg/m2 26.7 3.6 26.4 3.5
Total cholesterol, mg/dl 250 44 243 44
LDL-cholesterol, mg/dl 162 39 160 40
HDL-cholesterol, mg/dl 54 16 52 15
Triglycerides, mg/dl 159 (106–221) 150 (106–204)
Systolic blood pressure, mm Hg 140.4 18.1 140.0 17.9
Diastolic blood pressure, mm Hg 84.3 11.2 83.9 11.3
CRP, mg/l 1.3 (0.7–2.5) 1.5 (0.7–3.2)
White cell count, 103 cells/mm2 5.9 1.8 6.5 1.6
istribution of characteristics by MPO quartiles. Quartiles are based on values in control subjects.
PO quartiles and risk factors. †Pearson correlation between log-transformed serum MPO levels
BMI  body mass index; CAD  coronary artery disease; other abbreviations as in Table 1.
dds Ratios for Future CAD Events by MPO Quartile and for MPO a
Table 3 Odds Ratios for Future CAD Events by MPO Quartile an
MPO Quartile
1 2 3
MPO range, pmol/l 454 454–638 638–951
Case/control 219/559 276/559 318/560
Model 1 1 1.24 (1.00–1.54) 1.46 (1.18–1.
Model 2 1 1.15 (0.90–1.46) 1.33 (1.05–1.
Model 3 1 1.14 (0.89–1.46) 1.32 (1.03–1.
dds ratios and corresponding 95% confidence intervals calculated by conditional logistic regress
ere log transformed before analysis. Model 1: unadjusted. Model 2: adjustment for LDL-cholester
djustment for aforementioned variables and CRP (continuous variable). *Association between
onditional logistic regression, taking into account matching for age, gender, and enrollment time, for M
Abbreviations as in Tables 1 and 2.ndividuals in the top quartile had an OR of 1.49 (95% CI
.20 to 1.84) compared with those in the bottom quartile (p
0.001) (Model 1, Table 3). After adjustment for tradi-
ional risk factors, i.e., systolic blood pressure, LDL-
holesterol, HDL-cholesterol, BMI, smoking, and diabetes,
significant association between MPO quartiles and risk of
AD remained present (OR 1.36, 95% CI 1.07 to 1.73 for
op vs. bottom quartile; p  0.001) (Model 2, Table 3).
dditional adjustment for CRP weakened the association,
specially in the top quartile (OR 1.27, 95% CI 0.98 to 1.63
or top vs. bottom quartile; p  0.001) (Model 3, Table 3).
nalyses by MPO tertiles or quintiles did not essentially
hange the results.
Notably, the association was substantially stronger in
articipants who suffered from fatal CAD (OR 1.82, 95%
I 1.23 to 2.70, unadjusted; p  0.025) compared with
hose who suffered from nonfatal CAD (OR 1.35, 95% CI
.04 to 1.74; p  0.013) (Table 4). We did not identify a
tatistically significant interaction between gender and
p Value* R† p Value‡3 4
38–951 951
18/559 325/559 0.001
64/26 68/32 0.001
 7.7 65.5 7.8 0.05 0.036 0.04
(34) 3.1 (27) 0.99
0.001
(93) 14.8 (130)
(453) 52.2 (458)
 3.7 26.8 3.8 0.1 0.022 0.2
 45 241 44 0.001 0.068 0.001
 39 159 39 0.1 0.027 0.1
 15 50 15 0.001 0.096 0.001
(106–204) 150 (106–204) 0.2 0.048 0.005
 18.3 142.2 18.7 0.04 0.034 0.05
 11.5 85.2 11.6 0.07 0.027 0.1
(0.8–3.8) 2.7 (1.2–6.9) 0.001 0.25 0.001
 1.6 7.5 2.1 0.001 0.33 0.001
re presented as mean  SD, median (interquartile range), or % (n). *Association between serum
k factors. ‡p value corresponding to R.
ntinuous Variable
MPO as Continuous Variable
p Value* Ln(MPO)† p Value‡4
951
325/559
1.49 (1.20–1.84) 0.001 1.36 (1.19–1.56) 0.001
1.36 (1.07–1.73) 0.001 1.30 (1.12–1.52) 0.001
1.27 (0.98–1.63) 0.001 1.25 (1.07–1.47) 0.006
ing into account matching for age, gender, and enrollment time, per MPO quartile. CRP and MPO
-cholesterol, systolic blood pressure, BMI (continuous variables), smoking, and diabetes. Model 3:
uartiles and CAD risk. †Odds ratios and corresponding 95% confidence intervals calculated byartile
6
3
65.8
3.9
10.8
52.6
26.6
241
158
51
142
140.1
84.0
1.8
6.8
Data as Co
d for
80)
69)
68)
ion, tak
ol, HDL
MPO qPO as continuous variable. ‡p value corresponding to Ln(MPO).
M
a
a
1
0
t
i
l
r
c
h
2
1
u
t
D
s
c
m
t
h
f
b
[
h
(
0
D
M
e
v
r
m
i
fi
a
p
e
v
e
fi
a
C
C
n
b
h
(
p
a
d
c
t
(
v
m
m
o
v
m
a
m
r
o
s
Oi
A
163JACC Vol. 50, No. 2, 2007 Meuwese et al.
July 10, 2007:159–65 MPO and Future Risk of CADPO. Therefore, data for men and women were pooled,
lthough gender-specific analyses were also performed. The
ssociation of MPO with CAD was stronger in men (OR
.61, 95% CI 1.23 to 2.12 for top vs. bottom quartile; p 
.003) than in women (OR 1.17, 95% CI 0.84 to 1.62 for
op vs. bottom quartile; pNS) (Table 4). Further analyses
n low CAD risk subgroups showed that elevated MPO
evels (728 pmol/l) were also associated with an increased
isk of future CAD among subjects with either low LDL-
holesterol (130 mg/dl, OR 1.52 [95% CI 1.21 to 1.91]),
igh HDL-cholesterol (50 mg/dl, 1.59 [95% CI 1.24 to
.05]), or low CRP levels (2.0 mg/l, 1.42 [95% CI 1.14 to
.77]) (Table 5). The cut-off of 728 pmol/l was determined
sing the Youden index and represents the MPO concen-
ration at which (sensitivity  specificity  1) is maximal.
iscriminative ability of MPO. The AUC for a regres-
ion model indicates the percentage of CAD events that
ould be predicted successfully using the risk factors in that
odel. For MPO alone, the AUC was 0.55 (95% CI 0.53
o 0.57). The CRP levels, as a single risk factor, yielded the
ighest AUC (0.60 [95% CI 0.58 to 0.62]). Traditional risk
actors such as LDL- and HDL-cholesterol ranked in
etween (LDL 0.56 [95% CI 0.54 to 0.58], 1/HDL 0.59
95% CI 0.57 to 0.61]). Addition of MPO to the Framing-
am risk score did not significantly change the AUC
Framingham risk score alone AUC 0.59 [95% CI 0.57 to
.61], Framingham and MPO 0.60 [95% CI 0.58 to 0.62]).
Odds Ratios for Fatal and Nonfatal Future CADan Gender-Specific Odds Ratios by MPO Quarti
Table 4 Odds Ratios for Fatal and Nonfataland Gender-Specific Odds Ratios by
1 2
MPO range (pmol/l) 454 454–638
Fatal 1 1.45 (0.96–2
Nonfatal 1 1.17 (0.91–1
Male MPO range (pmol/l) 464 464–657
1 1.34 (1.02–1
Female MPO range (pmol/l) 446 446–607
1 0.91 (0.63–1
Abbreviations as in Tables 1 and 2.
dds Ratio and 95% Confidence Intervals for MPOn Subgroups Otherwise Associated With L w Risk
Table 5 Odds Ratio and 95% Confidence Intervals for MPOin Subgroups Otherwise Associated With Low Risk
MPO
<728 pmol/l
MPO
>728 pmol/l
LDL 130 mg/dl 1 1.52 (1.21–1.91)
LDL 130 mg/dl 1.42 (1.15–1.74) 1.81 (1.45–2.26)
HDL 50 mg/dl 1 1.59 (1.24–2.05)
HDL 50 mg/dl 1.80 (1.42–2.28) 2.22 (1.73–2.85)
CRP 2 mg/l 1 1.42 (1.14–1.77)
CRP 2 mg/l 2.15 (1.74–2.64) 2.36 (1.93–2.89)Mbbreviations as in Table 1.iscussion
yeloperoxidase can exert a plethora of proatherogenic
ffects, including oxidation of lipoproteins and induction of
ascular dysfunction (6–11). In support of a proatherogenic
ole of MPO in vivo, expression of human MPO in
acrophages of LDL receptor-deficient mice led to a 2-fold
ncrease in atherosclerotic lesion size (21). These intriguing
ndings indicate that MPO may be a marker for CAD risk,
mediator of atherogenesis, and a potential target for CAD
revention. The present study is the first to show that
levated serum levels of MPO in apparently healthy indi-
iduals are associated with an increased risk of future CAD
vents, largely independent of traditional risk factors. These
ndings may indicate that leukocyte activation or “priming”
ppears to be increased many years before the onset of overt
AD.
In this study, MPO is associated with the future risk of
AD in a primary prevention setting, i.e. among individuals
ot known to have heart disease. However, the relationship
etween MPO and CAD in these individuals is weaker than
as been reported in patients with acute coronary syndromes
ACS) (13–15). This may indicate that MPO level is a more
otent marker of plaque instability than of future CAD risk
nd/or atheroma burden. Because MPO is predominantly
erived from activated neutrophils and monocytes, in-
reased MPO in ACS is likely to reflect influx and activa-
ion of these cells in the vicinity of the unstable plaque
22–24). Of note, in atherosclerotic lesions removed during
ascular surgery, MPO colocalized predominantly with
acrophages within the lesion without significant involve-
ent of neutrophils (25). These findings indicate that the
rigin of MPO may differ between acute and chronic
ascular disease. Despite these findings, the present epide-
iologic study shows that MPO is associated with CAD in
primary prevention setting as well.
Interestingly, participants with high MPO levels were
ore likely to smoke. This observation is in line with a
ecent study that describes higher serum MPO levels and
ther markers of systemic inflammation in smokers without
evere airway systems (26). The origin and the effect of this
snadjusted)
e CAD Events
Quartile (Unadjusted)
PO Quartile
p Value3 4
638–951 951
1.44 (0.95–2.18) 1.82 (1.23–2.70) 0.03
1.47 (1.15–1.87) 1.35 (1.04–1.74) 0.01
657–985 985
1.54 (1.17–2.02) 1.61 (1.23–2.12) 0.003
607–894 894
1.20 (0.86–1.67) 1.17 (0.84–1.62) 0.3Eventle (U
Futur
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MPO and Future Risk of CAD July 10, 2007:159–65The utility of MPO measurement in clinical practice can
ot be based on the present study alone. We evaluated 2
spects of MPO measurements to address potential clinical
elevance for predicting cardiovascular risk in apparently
ealthy individuals. First, the association between MPO
nd CAD was, in line with previous studies, largely inde-
endent of traditional risk factors but attenuated by CRP.
oreover, the association of MPO with future CAD
mong apparently healthy individuals was weaker than that
f traditional cardiovascular risk factors and CRP. The
nadjusted OR (top vs. bottom quartile) of the traditional
isk factors in the EPIC study have been described else-
here and vary between 1.7 for LDL-cholesterol to 3.9 for
iabetes (27). The OR for CRP was 2.4, 1.66 after
djustment for traditional risk factors, compared with 1.49
nd 1.36, respectively, for MPO. Second, we determined
he ability of MPO to increase the AUC of cardiovascular
vent prediction. Receiver-operating characteristic analysis
valuates sensitivity and specificity at each possible cut-off
oint of a clinical test and is a widely used method to judge
he discriminative ability, and therefore clinical utility, of
ovel risk factors (28). However, the methodology is de-
ated, because it is relatively insensitive (29). We did not
bserve a significant increase in the AUC by adding MPO
o the Framingham risk score. Additional analyses and
tudies will be helpful in assessing the clinical utility of
outine measurement of serum MPO levels in community-
ased risk assessment of apparently healthy subjects. The
PO levels have been shown to have additional prognostic
alue in the acute setting (13–15).
tudy limitations. Several aspects of the current study
arrant attention. First, CAD events were ascertained
hrough death certification and hospital admission data,
hich could lead both to underascertainment and misclas-
ification of cases. However, previous validation studies in
his cohort indicate high specificity of such case ascertain-
ent (30). Second, serum levels of MPO and lipoproteins
ere determined in a single nonfasting sample that was
btained at a nonuniform time of the day. Diurnal variation,
ariation over time, e.g., temporarily increased levels due to
nfection and differences in the time span from the last meal,
ould have affected these variables. In this respect, measure-
ent of specific MPO products, such as chlorotyrosine in
DL, may provide a better indication of MPO activity and
PO-induced damage (8,9). Furthermore, it has recently
een suggested that MPO levels after heparin administra-
ion are a better reflection of subendothelial MPO (31).
owever, these analyses could not be performed in the
resent study. Third, sample storage at 80°C for 8 to 12
ears may have affected the MPO concentration. However,
his would affect samples of both cases and controls. This
tudy does leave us to assume similar effects in samples
ontaining low and high MPO. Random measurement
rror in both case ascertainment and time variations would
ead to an underestimation of any relationships between risk
actors and CAD risk. The extent of measurement error,owever, is unlikely to differ from those for other risk factors
r from other prospective studies. Finally, elevated MPO
evels may also reflect subclinical atherosclerotic burden in
articipants who eventually developed symptomatic CAD.
onclusions
levated serum concentrations of MPO are associated
ith an increased risk of future CAD in apparently
ealthy individuals. It is clear that elevation of inflam-
atory markers, such as MPO and CRP, and their
nteractions precede the onset of CAD by years. This
nderscores the potential relevance of exploration of
ntiinflammatory strategies.
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